Biosyent Historical Balance Sheet

RX Stock

CAD 11.26 0.08 0.71%

Trend analysis of Biosyent balance sheet accounts such as Total Stockholder Equity of 36.5 M, Property Plant And Equipment Net of 1.5 M, Retained Earnings of 28.9 M or Accounts Payable of 5.3 M provides information on Biosyent's total assets, liabilities, and equity, which is the actual value of Biosyent to its prevalent stockholders. By breaking down trends over time using Biosyent balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Biosyent latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biosyent is a good buy for the upcoming year.

Biosyent Inventory

6.19 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Biosyent Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Biosyent at a specified time, usually calculated after every quarter, six months, or one year. Biosyent Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Biosyent and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Biosyent currently owns. An asset can also be divided into two categories, current and non-current.

Biosyent Balance Sheet Chart

At this time, Biosyent's Cash And Short Term Investments are fairly stable compared to the past year. Common Stock Shares Outstanding is likely to climb to about 13.5 M in 2024, whereas Net Debt is likely to drop (3.9 M) in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Non Current Liabilities Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Biosyent assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Biosyent books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Biosyent balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Biosyent are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Biosyent's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Biosyent current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	1.6M	1.4M	1.2M	1.2M
Total Assets	37.2M	40.5M	41.5M	43.6M

Short Long Term Debt Total Total Assets

Biosyent balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Current Deferred Revenue	Net Receivables	Short Term Investments	Common Stock	Other Liab
Total Assets		-0.04	-0.24	0.96	1.0	0.78	-0.5	1.0	0.96	0.57	0.93	0.15	0.99	0.15	0.83	0.59	-0.14	0.96	1.0	0.25	0.65	0.4	0.96	0.86	-0.64	0.61
Short Long Term Debt Total	-0.04		0.41	-0.1	-0.03	-0.08	-0.41	-0.09	-0.09	0.37	-0.19	0.13	0.02	0.94	-0.26	0.07	-0.5	-0.1	-0.02	-0.95	0.14	0.33	-0.07	-0.27	0.45	0.12
Other Current Liab	-0.24	0.41		-0.11	-0.26	-0.22	0.08	-0.28	-0.15	-0.11	-0.32	-0.16	-0.23	0.36	-0.14	-0.21	0.0	-0.15	-0.23	-0.42	-0.26	0.17	-0.32	-0.22	0.2	-0.21
Total Current Liabilities	0.96	-0.1	-0.11		0.94	0.78	-0.39	0.95	0.99	0.46	0.9	0.02	0.93	0.09	0.89	0.48	-0.12	0.99	0.96	0.32	0.51	0.48	0.91	0.87	-0.75	0.47
Total Stockholder Equity	1.0	-0.03	-0.26	0.94		0.76	-0.52	1.0	0.95	0.58	0.93	0.15	0.99	0.16	0.82	0.59	-0.14	0.94	1.0	0.23	0.68	0.37	0.96	0.85	-0.62	0.65
Property Plant And Equipment Net	0.78	-0.08	-0.22	0.78	0.76		-0.43	0.77	0.74	0.53	0.78	0.45	0.78	-0.03	0.6	0.8	-0.01	0.87	0.78	0.23	0.29	0.54	0.68	0.62	-0.6	0.1
Net Debt	-0.5	-0.41	0.08	-0.39	-0.52	-0.43		-0.49	-0.32	-0.99	-0.31	-0.2	-0.61	-0.38	0.02	-0.56	0.42	-0.41	-0.52	0.37	-0.66	-0.61	-0.35	0.0	-0.16	-0.48
Retained Earnings	1.0	-0.09	-0.28	0.95	1.0	0.77	-0.49		0.96	0.56	0.93	0.13	0.99	0.11	0.83	0.59	-0.11	0.95	1.0	0.29	0.66	0.36	0.96	0.87	-0.65	0.63
Accounts Payable	0.96	-0.09	-0.15	0.99	0.95	0.74	-0.32	0.96		0.4	0.91	0.02	0.93	0.12	0.92	0.44	-0.07	0.97	0.96	0.32	0.52	0.37	0.95	0.92	-0.76	0.52
Cash	0.57	0.37	-0.11	0.46	0.58	0.53	-0.99	0.56	0.4		0.39	0.24	0.68	0.34	0.06	0.63	-0.39	0.5	0.59	-0.31	0.65	0.65	0.42	0.08	0.07	0.46
Non Current Assets Total	0.93	-0.19	-0.32	0.9	0.93	0.78	-0.31	0.93	0.91	0.39		0.24	0.88	0.02	0.88	0.55	-0.02	0.92	0.91	0.37	0.54	0.32	0.88	0.87	-0.67	0.52
Non Currrent Assets Other	0.15	0.13	-0.16	0.02	0.15	0.45	-0.2	0.13	0.02	0.24	0.24		0.16	0.07	-0.04	0.72	-0.09	0.13	0.13	-0.18	0.18	-0.12	0.04	0.01	0.25	0.06
Cash And Short Term Investments	0.99	0.02	-0.23	0.93	0.99	0.78	-0.61	0.99	0.93	0.68	0.88	0.16		0.18	0.74	0.64	-0.18	0.94	0.99	0.17	0.7	0.45	0.93	0.79	-0.57	0.64
Common Stock Shares Outstanding	0.15	0.94	0.36	0.09	0.16	-0.03	-0.38	0.11	0.12	0.34	0.02	0.07	0.18		0.0	0.04	-0.58	0.06	0.16	-0.87	0.23	0.27	0.15	-0.04	0.29	0.27
Inventory	0.83	-0.26	-0.14	0.89	0.82	0.6	0.02	0.83	0.92	0.06	0.88	-0.04	0.74	0.0		0.26	0.03	0.86	0.82	0.47	0.32	0.14	0.87	0.95	-0.84	0.38
Other Current Assets	0.59	0.07	-0.21	0.48	0.59	0.8	-0.56	0.59	0.44	0.63	0.55	0.72	0.64	0.04	0.26		-0.14	0.59	0.59	0.02	0.35	0.29	0.45	0.35	-0.2	0.22
Other Stockholder Equity	-0.14	-0.5	0.0	-0.12	-0.14	-0.01	0.42	-0.11	-0.07	-0.39	-0.02	-0.09	-0.18	-0.58	0.03	-0.14		-0.09	-0.15	0.46	-0.3	-0.17	-0.1	0.1	-0.26	-0.22
Total Liab	0.96	-0.1	-0.15	0.99	0.94	0.87	-0.41	0.95	0.97	0.5	0.92	0.13	0.94	0.06	0.86	0.59	-0.09		0.96	0.31	0.48	0.51	0.89	0.85	-0.74	0.41
Total Current Assets	1.0	-0.02	-0.23	0.96	1.0	0.78	-0.52	1.0	0.96	0.59	0.91	0.13	0.99	0.16	0.82	0.59	-0.15	0.96		0.23	0.66	0.41	0.96	0.85	-0.63	0.62
Short Term Debt	0.25	-0.95	-0.42	0.32	0.23	0.23	0.37	0.29	0.32	-0.31	0.37	-0.18	0.17	-0.87	0.47	0.02	0.46	0.31	0.23		-0.05	-0.23	0.3	0.49	-0.66	-0.02
Intangible Assets	0.65	0.14	-0.26	0.51	0.68	0.29	-0.66	0.66	0.52	0.65	0.54	0.18	0.7	0.23	0.32	0.35	-0.3	0.48	0.66	-0.05		0.17	0.62	0.39	0.02	0.91
Current Deferred Revenue	0.4	0.33	0.17	0.48	0.37	0.54	-0.61	0.36	0.37	0.65	0.32	-0.12	0.45	0.27	0.14	0.29	-0.17	0.51	0.41	-0.23	0.17		0.23	0.08	-0.22	-0.01
Net Receivables	0.96	-0.07	-0.32	0.91	0.96	0.68	-0.35	0.96	0.95	0.42	0.88	0.04	0.93	0.15	0.87	0.45	-0.1	0.89	0.96	0.3	0.62	0.23		0.91	-0.7	0.61
Short Term Investments	0.86	-0.27	-0.22	0.87	0.85	0.62	0.0	0.87	0.92	0.08	0.87	0.01	0.79	-0.04	0.95	0.35	0.1	0.85	0.85	0.49	0.39	0.08	0.91		-0.83	0.47
Common Stock	-0.64	0.45	0.2	-0.75	-0.62	-0.6	-0.16	-0.65	-0.76	0.07	-0.67	0.25	-0.57	0.29	-0.84	-0.2	-0.26	-0.74	-0.63	-0.66	0.02	-0.22	-0.7	-0.83		-0.01
Other Liab	0.61	0.12	-0.21	0.47	0.65	0.1	-0.48	0.63	0.52	0.46	0.52	0.06	0.64	0.27	0.38	0.22	-0.22	0.41	0.62	-0.02	0.91	-0.01	0.61	0.47	-0.01

Click cells to compare fundamentals

Biosyent Account Relationship Matchups

Biosyent balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	31.0M	33.6M	37.2M	40.5M	41.5M	43.6M
Other Current Liab	198.8K	328.8K	98.7K	318.0K	138.4K	228.7K
Total Current Liabilities	3.4M	5.1M	4.1M	5.7M	5.5M	5.8M
Total Stockholder Equity	25.8M	26.8M	31.6M	33.4M	34.8M	36.5M
Property Plant And Equipment Net	2.5M	2.2M	1.9M	1.7M	1.4M	1.5M
Net Debt	(11.6M)	(18.6M)	(16.5M)	(6.5M)	(3.7M)	(3.9M)
Retained Earnings	17.5M	19.1M	24.1M	25.9M	27.5M	28.9M
Accounts Payable	2.9M	3.7M	3.6M	5.1M	5.1M	5.3M
Cash	13.4M	20.3M	18.0M	7.9M	4.9M	5.4M
Non Current Assets Total	4.1M	3.8M	3.1M	3.3M	5.7M	5.9M
Cash And Short Term Investments	22.0M	25.6M	28.2M	28.7M	26.2M	27.5M
Common Stock Shares Outstanding	13.9M	13.1M	12.9M	12.5M	12.2M	13.5M
Liabilities And Stockholders Equity	31.0M	33.6M	37.2M	40.5M	41.5M	43.6M
Inventory	2.1M	2.1M	2.2M	4.5M	5.9M	6.2M
Other Current Assets	648.8K	307.6K	456.0K	255.0K	243.5K	163.3K
Other Stockholder Equity	1.2M	1.5M	1.8M	2.2M	2.3M	3.1M
Total Liab	5.2M	6.8M	5.6M	7.1M	6.8M	7.1M
Total Current Assets	26.8M	29.8M	34.1M	37.1M	35.9M	37.7M
Intangible Assets	1.0M	1.0M	874.0K	1.2M	1.2M	660.8K
Current Deferred Revenue	99.1K	934.4K	313.6K	164.4K	134.5K	138.0K
Net Receivables	2.1M	1.8M	3.2M	3.7M	3.5M	3.7M
Accumulated Other Comprehensive Income	(105.3K)	(166.7K)	(185.3K)	(143.1K)	(177.5K)	(168.6K)
Short Term Investments	8.5M	5.3M	10.2M	20.8M	21.3M	22.3M
Common Stock	7.2M	6.4M	5.8M	5.4M	5.1M	5.4M
Other Liab	102.9K	79.7K	80.2K	182.4K	209.7K	153.4K
Net Tangible Assets	24.7M	25.8M	30.7M	32.3M	37.1M	21.9M
Other Assets	686.5K	758.8K	406.5K	639.1K	1.0	0.95
Non Current Liabilities Total	1.8M	1.6M	1.5M	1.4M	1.2M	851.1K
Property Plant Equipment	2.4M	2.1M	1.8M	1.6M	1.9M	961.5K
Deferred Long Term Liab	72.0K	131.0K	124.1K	170.6K	196.2K	98.8K
Net Invested Capital	25.8M	26.8M	31.6M	33.4M	34.8M	31.8M
Net Working Capital	23.5M	24.6M	29.9M	31.4M	30.3M	29.1M
Capital Stock	7.2M	6.4M	5.8M	5.4M	5.1M	5.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Biosyent Stock Analysis

When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biosyent Historical Balance Sheet

Biosyent Inventory

6.19 Million

About Biosyent Balance Sheet Analysis

Biosyent Balance Sheet Chart

Total Assets

Total Current Liabilities

Biosyent balance sheet Correlations

Biosyent Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biosyent balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Biosyent Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Retained Earnings	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Retained Earnings

Cash	- 0.99	Net Debt
Short Term Debt	- 0.95	Short Long Term Debt Total
Short Term Debt	- 0.87	Common Stock Shares Outstanding
Common Stock	- 0.84	Inventory
Common Stock	- 0.83	Short Term Investments
Common Stock	- 0.76	Accounts Payable